A proteomics-MM/PBSA dual approach for the analysis of SARS-CoV-2 main protease substrate peptide specificity

Gallo, Gloria; Barcick, Uilla; Coelho, Camila; Salardani, Murilo; Camacho, Maurício F.; Cajado-Carvalho, Daniela; Loures, Flávio V.; Serrano, Solange Maria de Toledo; Hardy, Leon; Zelanis, André; Würtele, Martin.
Peptides, v. 154, 170814, ago. 2022
Artículo en Inglés | SES-SP, SESSP-IBPROD, SES-SP | ID: bud-4377

Documentos relacionados

  1. A proteomics-MM/PBSA dual approach for the analysis of SARS-CoV-2 main protease substrate peptide specificity.
  2. Heterogeneity of SARS-CoV-2 virus produced in cell culture revealed by shotgun proteomics and supported by genome sequencing.
  3. DIA-Based Proteome Profiling of Nasopharyngeal Swabs from COVID-19 Patients.
  4. Optimization of quenched fluorescent peptide substrates of SARS-CoV-2 3CL<sup>pro</sup> main protease (Mpro) from proteomic identification of P6-P6' active site specificity.
  5. Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow.
  6. Preliminary Structural Data Revealed That the SARS-CoV-2 B.1.617 Variant's RBD Binds to ACE2 Receptor Stronger Than the Wild Type to Enhance the Infectivity.
  7. Blue Biotechnology: Computational Screening of <i>Sarcophyton</i> Cembranoid Diterpenes for SARS-CoV-2 Main Protease Inhibition.